- Scientists & Leadership
- ISB Research
- Education & Outreach
SEATTLE (Tuesday, August 19, 2003) – The Institute for Systems Biology (ISB) a non-profit research institute dedicated to the study and application of systems biology today announced the appointment of Roger M. Perlmutter, M.D., Ph.D., as chairman of its board of directors.
Dr. Perlmutter currently serves as the Executive Vice President, Research and Development, at Amgen Inc., where he oversees the company’s worldwide research and development operations. Dr. Perlmutter has a longstanding relationship with ISB, and has been a member of the board since the Institute’s inception in January 2000.
“Roger has had two exceptionally successful careers—first as an academic interested in immunology and now as a leader in pharma and biotech research,” said Dr. Leroy Hood, President of the Institute for Systems Biology. “He has exhibited throughout a remarkable ability to organize and integrate diverse skills and opportunities. Accordingly, Roger will bring deep insights into the interplay between academia and industry and striking and integrative leadership skills.”
Dr. Perlmutter joined Amgen as Executive Vice President, Research and Development, in January 2001. Before joining Amgen, Dr. Perlmutter was an executive vice president at Merck Research Laboratories. From 1984 to 1997 he was a faculty member in the Departments of Medicine and Biochemistry, and later Professor and Chairman of the Department of Immunology at the University of Washington, where he continues as an Affiliate Professor. He was also an Investigator of the Howard Hughes Medical Institute at the University of Washington during this period. A graduate of Reed College, Portland, Oregon, Dr. Perlmutter received his M.D. and Ph.D. degrees from Washington University, St. Louis, Missouri in 1979. He is a past president of the American Association of Immunologists, and a Fellow of the American Academy of Arts and Sciences.
“The concept of systems biology is moving to the forefront, and the Institute is on the cutting edge,” stated Perlmutter. “I look forward to working more closely with the team of scientists at the ISB, and welcome this opportunity to take an expanded leadership role in an effort that holds enormous promise for scientific advances that will transform biology and medicine in the years to come.”
Systems biology combines biology, technology, and computer modeling to study biological information (DNA, RNA, protein, protein interactions, biomodules, cells, tissues, etc). Using this approach, scientists plan to identify strategies that will personalize medicine, both by predicting illness in the individual, and by prescribing preventative remedies.
“We look forward to partnering with Roger in this exciting adventure of realizing the enormous potential and catalyzing the revolutionary changes embedded in the mission of the Institute,” stated Hood.